Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting indolent non-Hodgkin’s lymphoma (iNHL).
The funding will support the expansion and completion of the ongoing Phase I/II SIDNEY trial and prepare for a registrational trial.
Go deeper with GlobalData
The Institute for Follicular Lymphoma Innovation (IFLI), a new US investor, contributed $9m to the funding round, $5m of which will be immediately available to Enterome, with an additional $4m in conditional tranches.
Current shareholders Seventure Partners, SymBiosis, Lundbeckfonden BioCapital, the US Leukemia & Lymphoma Society Therapy Acceleration Program and Primo Capital have collectively invested an additional $10m.
EO2463 is an off-the-shelf immunotherapy candidate that joins four synthetic OncoMimics peptides.
EO2463 selectively targets several B-cell markers and is designed to destroy malignant B lymphocytes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBy covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape.
Recently, Enterome announced its plan to present new data at the International Conference on Malignant Lymphoma (ICML) in Lugano on 21 June 2025.
The data will demonstrate the impact of EO2463 in conjunction with standard care for relapsed and refractory iNHL subjects.
Enterome noted that OncoMimics, the basis for EO2463, was inspired by the microbial origin of specific autoimmune conditions.
It leverages machine learning and AI to detect microbial proteins that mimic the effect, structure or actions of certain cancer antigens.
Enterome CEO Pierre Bélichard stated: “We are currently generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase I/II SIDNEY clinical trial.
“Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy.
“This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase III trial of this candidate for the ‘watch-and-wait’ iNHL population.”
